Bright Minds Biosciences (DRUG) Non-Current Assets (2020 - 2026)
Bright Minds Biosciences' (DRUG) quarterly Non-Current Assets came in at $52778.4 in Q1 2026, down 50.99% YoY from $107682.7 in Q1 2025, and down 20.15% on a QoQ basis from $66100.3 in Q4 2025.
Bright Minds Biosciences (DRUG) Non-Current Assets (2020 - 2026) Analysis & Trends
Bright Minds Biosciences (DRUG) has 7 years of Non-Current Assets data on file, last reported at $52778.4 in Q1 2026.
- Quarterly Non-Current Assets fell 50.99% year-over-year to $52778.4 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $293322.2 (down 10.97% YoY) and the FY2025 annual result came in at $81359.9, down 5.67% from the prior year.
- Non-Current Assets eased to $52778.4 in Q1 2026, from $66100.3 in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $126700.3 in Q4 2024 to a low of $8828.5 in Q2 2024.
- A 5-year average of $70965.3 and a median of $75921.0 in 2023 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets soared 6601.37% — and 2024, when it slumped 85.97%.
- Tracing DRUG's Non-Current Assets over 5 years: stood at $88957.6 in 2022, then plunged by 60.12% to $35478.1 in 2023, then soared by 257.12% to $126700.3 in 2024, then tumbled by 47.83% to $66100.3 in 2025, then decreased by 20.15% to $52778.4 in 2026.
- The last three Non-Current Assets figures came in at $52778.4 (Q1 2026), $66100.3 (Q4 2025), and $81359.9 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Bright Minds Biosciences | 733.05 Mn | 733.05 Mn | - | 52,778.45 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 52,778.45 |
| Dec 31, 2025 | 66,100.30 |
| Sep 30, 2025 | 81,359.87 |
| Jun 30, 2025 | 93,083.59 |
| Mar 31, 2025 | 107,682.66 |
| Dec 31, 2024 | 126,700.29 |
| Sep 30, 2024 | 86,249.60 |
| Jun 30, 2024 | 8,828.52 |
| Mar 31, 2024 | 22,402.91 |
| Dec 31, 2023 | 35,478.07 |
| Sep 30, 2023 | 49,539.48 |
| Jun 30, 2023 | 62,924.84 |
| Mar 31, 2023 | 75,920.96 |
| Dec 31, 2022 | 88,957.62 |
| Sep 30, 2022 | 106,472.68 |
| Sep 30, 2021 | 1,588.82 |
| Sep 30, 2020 | 1,500.85 |